{"id":15108,"date":"2021-07-22T12:28:00","date_gmt":"2021-07-22T12:28:00","guid":{"rendered":"https:\/\/clinlabint.com\/?p=15108"},"modified":"2021-07-22T12:28:00","modified_gmt":"2021-07-22T12:28:00","slug":"probiogen-lava-therapeutics-close-second-cell-line-development-agreement","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/probiogen-lava-therapeutics-close-second-cell-line-development-agreement\/","title":{"rendered":"ProBioGen, LAVA Therapeutics close second cell line development agreement"},"content":{"rendered":"<p><img decoding=\"async\" class=\"alignnone size-medium wp-image-15109\" src=\"https:\/\/clinlabint.com\/wp-content\/uploads\/sites\/2\/2021\/07\/probiogen_logo_web2-300x116.jpg\" alt=\"ProBioGen\" width=\"300\" height=\"116\" title=\"\" srcset=\"https:\/\/clinlabint.com\/wp-content\/uploads\/sites\/2\/2021\/07\/probiogen_logo_web2-300x116.jpg 300w, https:\/\/clinlabint.com\/wp-content\/uploads\/sites\/2\/2021\/07\/probiogen_logo_web2-768x296.jpg 768w, https:\/\/clinlabint.com\/wp-content\/uploads\/sites\/2\/2021\/07\/probiogen_logo_web2-705x272.jpg 705w, https:\/\/clinlabint.com\/wp-content\/uploads\/sites\/2\/2021\/07\/probiogen_logo_web2.jpg 794w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/p>\n<p>ProBioGen and LAVA Therpuetics N.V. have closed a second cell line development agreement to support a bispecific gamma-delta T cell engager (TCE) candidate in LAVA&#8217;s pipeline.<\/p>\n<p>Under the agreement and using its\u00a0CHO.RiGHT expression platform, including its\u00a0<a href=\"https:\/\/www.probiogen.de\/directedluck-transposase-with-epigenetic-targeting.html\" target=\"_blank\" rel=\"noopener noreferrer\">DirectedLuck<\/a> Transposase technology for the generation of stable high-titer cell lines, ProBioGen will conduct cell line development of a novel gamma-delta bsTCE.<\/p>\n<p>Dr. Lutz Hilbrich, ProBioGen&#8217;s Chief Executive Officer, said: &#8220;We are delighted to continue our collaboration with LAVA to develop cell lines for another novel gamma-delta bsTCE. Our proven cell line development platform, which also includes our Transposase technology, is perfectly suited for novel protein formats.&#8221;<\/p>\n<p>Stephen Hurly, Chief Executive Officer and President of LAVA Therapeutics, commented: &#8220;Based on the great results from our previous agreement, we would look forward working with ProBioGen again. ProBioGen exceeded our expectations and proved to be a scientifically driven partner with a proven development platform and a dedicated analytical panel for bispecific antibody formats.&#8221;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>ProBioGen and LAVA Therpuetics N.V. have closed a second cell line development agreement to support a bispecific gamma-delta T cell engager (TCE) candidate in LAVA&#8217;s pipeline. Under the agreement and using its\u00a0CHO.RiGHT expression platform, including its\u00a0DirectedLuck Transposase technology for the generation of stable high-titer cell lines, ProBioGen will conduct cell line development of a novel [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":15110,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[35],"tags":[],"class_list":["post-15108","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-e-news"],"_links":{"self":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/15108"}],"collection":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/comments?post=15108"}],"version-history":[{"count":2,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/15108\/revisions"}],"predecessor-version":[{"id":15112,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/15108\/revisions\/15112"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/media\/15110"}],"wp:attachment":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/media?parent=15108"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/categories?post=15108"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/tags?post=15108"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}